Expanded Access by USA FDA for Investigational Drugs
In the United States, the approval process for unregistered medicinal products under Early Access Program (EAP) is known as Expanded Access
Deep dive and engage in insightful discourse driven by concurrent global regulatory scenarios, industry trends and Artixio’s real-time experience across the product value chain. Whitepapers, research articles, landscape reports and case studies to help you stay ahead of the curve.